addendum/reply to HIV PrEP: cabotegravir shines

 

Here is email form Albert Liu (forwarded with his permission), who was involved in the study, with link to FDA application for CAB approval and comment (not available to review) that study in a small trial of cis-gender women at high risk in Africa had dramatic protection from (89%) with CAB over TDF/FTC!!!

 

geoff

 

--------

 

Hi Geoff,

 

Thanks for your post about cabotegravir for PrEP! (we were one of the sites conducting the HPTN 083 trial)

 

I did want to let you know that a sister trial HPTN 084 was recently stopped early with similar findings of superiority of CAB over TDF/FTC in cisgender women in Africa:

 

https://www.nih.gov/news-events/news-releases/nih-study-finds-long-acting-injectable-drug-prevents-hiv-acquisition-cisgender-women

 

https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women

 

So we do have evidence of CAB safety and efficacy in cis MSM, trans women, and cisgender women.   Viiv has submitted an application for approval of CAB for PrEP which is currently under review:

 

https://viivhealthcare.com/en-gb/media/press-releases/2021/may/viiv-healthcare-initiates-rolling/

 

Thanks, Al

 

Albert Liu, MD, MPH

Clinical Research Director
Bridge HIV  |  Population Health Division | San Francisco Department of Public Health

25 Van Ness Ave, Suite 100, San Francisco, CA 94102

Comments

Popular posts from this blog

air pollution and heart disease

resistant hypertension: are diuretics harmful?

Body Roundness Index is better predictor than BMI for clinical problems